DPPC-PFOB乳剂在急性呼吸窘迫症(ARDS)治疗中的应用
详细信息    查看官网全文
摘要
ARDS是严重感染、创伤、休克等肺内外因素作用后出现的以进一步呼吸窘迫和难治性低氧血症为临床特点的综合症。ARDS在机械通气治疗取得重大进展的同时,ARDS患者住院死亡率仍高达40%。ARDS的始发因素是多种治病因素导致的"炎症级联反应"。其中,肺泡Ⅱ型上皮细胞受损使肺泡表面活性物质生成、摄取、利用均减少,导致肺泡表面张力增大,促进肺泡萎陷。临床研究表明,肺表面活性物质能够有效改善ARDS患者肺氧合功能。因此,我们选择DPPC(二棕榈酰磷脂酰胆碱)作为载体,同时结合全氟碳化合物(PFOB)的携氧性能,制备了DPPC-PFOB乳剂,将其成功应用于ARDS治疗中,起到了快速改善低氧血症的效果。
ARDS is a syndrome with the clinical characteristics,such as serious infection, trauma, shock and other reasons about lung internal and external factors which will lead to further refractory hypoxemia and respiratory distress.Among these,the damage of the epithelial cells of alveolar type II has the influence on the generation、absorbtion and use of surface active substances,which also lead to the increase of alveolar surface tension and the atrophy of pulmonary alveoli.We take use of the rabbit model of acute respiratory distress syndrome(ARDS) to evalute the effect on the lung of DPPC-PFOB emulsion.
引文
[1]Yao,Yanjie;Zhang,Minmin;Liu,Tian;Zhou juan.ACS Appl.Mater.Interfaces.2015,7:18369-18378

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700